210537-40-9

Upstream product

• 921-48-2 (2S,3S)-2-chloro-3-methylpentanoic acid 
• 32644-17-0 (S)-2-bromo-(S)-3-methylpentanoic acid 
• 73-32-5 L-isoleucine 
• 28977-69-7 (S)-3-methylpentanoic acid chloride 
• 1730-92-3 (3S)-methylvaleric acid 
• 42072-39-9 (S)-3-methyl-1-pentanol 
• 425-75-2 trifluoromethanesulfonic acid ethyl ester 
• 133729-84-7 (4S,3'S)-3-(3'-methyl-1'-oxopentyl)-4-benzyl-2-oxazolidinone 

Relevant academic research and scientific papers

Amelioration of neurological disorders by the administration of (2R),(3S), and/or (2S),3(S) stereoisomers of valnoctamide

The present invention generally relates to the individual stereoisomers of the drug valnoctamide (a mixture of four stereoisomer kinds, VCD-valmethamide or 2-ethyl-3-methyl pentanamide) useful in treatment of neurological and psychotic disorders such as d

Absolute configuration of the four stereoisomers of valnoctamide (2- ethyl-3-methyl valeramide), a potentially new stereospecific antiepileptic and CNS drug

Valnoctamide (2-ethyl-3-methyl valeramide, Nirvanil, VCD), a mild tranquilizer endowed with anticonvulsant properties, exhibits diastereoselective and enantioselective pharmacokinetics in healthy subjects and epileptic patients. The purpose of this paper